World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 28 April 2013
Main ID:  ChiCTR-TRC-09000591
Date of registration: 2010-06-26
Primary sponsor: Beijing Anzhen Hospital
Public title: Comparison of two different ablation strategies in patients with persistent atrial fibrillaiton: a randomized controlled trial
Scientific title: Comparison of two different ablation strategies in patients with persistent atrial fibrillaiton: a randomized controlled trial
Date of first enrolment: 2009-11-13
Target sample size: Group A:73;Group B:73;Total:146;
Recruitment status: Recruiting
URL:  http://www.chictr.org/en/proj/show.aspx?proj=809
Study type:  Interventional
Study design:  Randomized parallel control  
Countries of recruitment
China
Contacts
Name: Caihua Sang 
Address:  Department of Cardiology-Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Chaoyang District, Beijing 100029, P. R. China 100029
Telephone: +86 10 64456587
Email: sch9613070@yahoo.com.cn
Affiliation: 
Name: Changsheng Ma 
Address:  Department of Cardiology-Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Chaoyang District, Beijing 100029, P. R. China. 100029
Telephone: +86 10 64456587
Email: chshma@vip.sina.com
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years old;
2. Experienced twice persistent symptomatic AF episodes documented by ECG with an interval of at least 7 days in latest 6 months;
3. With symptomatic AF respondent to amiodarone;
4. Had willingness, ability and commitment to participate in follow-up.

Exclusion criteria: 1. Experienced coronary artery bypass graft surgery within 1 year of screening;
2. With uncontrolled congestive heart failure;
3. Having significant valvular disease and/or prosthetic heart valve(s);
4. With myocardial infarction or stroke within 3 months of screening;
5. With Significant congenital heart disease;
6. Ejection fraction was <35% measured by echocardiography;
7. Allergic to contrast media;
8. Severe electrolyte abnormalities within 1 month of treatment;
9. Contraindication to warfarin or heparin;
10. Pulmonary emboli or stroke within 1 year before screening;
11. Left atrial (LA) thrombus measured by pre-procedure transesophageal echocardiography;
12.Pregnant women;
13.having any contraindication to right or left sided heart catheterization;
14.Poor general health ;
15.Life expectancy less than 1 year.


Age minimum: 18
Age maximum: 80
Gender: Both
Health Condition(s) or Problem(s) studied
atrial fibrillation
Intervention(s)
Group A:circumferential pulmonary vein ablation+atrial linear ablation(left atrial roof, mitral isthmus and cavo-tricuspid isthmus);Group B:circumferential pulmonary vein ablation+atrial linear ablation(left atrial roof, mitral isthmus and cavo-tricuspid isthmus)+complex fractionated atrial electrogram (CFAE) ablation;Total:;
Primary Outcome(s)
Conversion proportion to sinus rhythm after initial ablation procedure (including either by cardiove;
Secondary Outcome(s)
Atrial fibrillation- and atrial flutter- free proportion without antiarrhythmic-drug adnimistration ;
Secondary ID(s)
Source(s) of Monetary Support
Self funding
Secondary Sponsor(s)
Beijing Anzhen Hospital
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history